What Governs Tablet Hardness and Ejection Force in High-Speed Direct Compression?

In direct compression of medium-to-high-dose actives, Compressol™ ProTab is introduced at 30–90 wt% of the core blend, with a typical working level of 65 wt% for tablets targeted at 100–800 mg. The compendial control set includes USP-NF <1062> for tablet compression characterization, USP <1174> for powder flow, Ph.Eur. 2.9.34 for bulk and tapped density, ICH Q3D elemental impurity limits, and FDA 21 CFR 211.110 for in-process sampling and control. The downstream process begins with sieving through a 0.5 mm screen, followed by blending in a 50–600 L bin blender at 12–25 rpm for 15 min; magnesium stearate is then introduced at 0.5% w/w and lubricated for 3 min. Compression is performed on a rotary press with D-tooling at 50–80 kN main compression force, 10 kN precompression, and 30–60 rpm, producing tablets with crushing strength 80–150 N and friability <0.8% when tested according to USP <1216>. The terminal product is an immediate-release compressed tablet. The operational boundary is pre-drying at RH >60% because the saccharide surface adsorbs moisture, and lubrication beyond 5 min reduces interparticulate bonding and ejection force control.

For low-dose capsule filling where active content accounts for less than 5% of the fill weight, Compressol™ ProTab is incorporated at 10–85 wt% depending on dosator chamber volume, with fill weight typically adjusted to 100–200 mg in size 0–2 two-piece hard capsules. The relevant standards are USP <905> uniformity of dosage units, USP <711> dissolution, Ph.Eur. 2.9.5 uniformity of mass, and ICH Q3D. The manufacturing sequence includes pre-sieving of the active and Compressol™ ProTab through a 0.5 mm sieve, dry blending in a tumble blender at 20 rpm for 10–15 min, and encapsulation on a dosator or tamping-pin machine with dosing chamber height set to compensate for the saccharide’s bulk density. Fill weight variation is maintained within ±5%, and loss on drying is controlled below 0.5% by keeping processing-room relative humidity below 60% RH. The terminal finished product is a hard gelatin or HPMC capsule containing an immediate-release powder blend. A formulation limit emerges when hydrophobic actives require pre-milling: the saccharide excipient should be withheld from the mills to avoid amorphous surface generation that can increase moisture uptake and drive capsule fill-weight drift during encapsulation.

When Roller Compaction Pressure Exceeds 6 MPa in Dry Granulation

When roller compaction pressure exceeds 6 MPa, the brittle fracture mode of Compressol™ ProTab becomes the controlling variable in dry granulation of moisture-sensitive APIs. The excipient is added at 20–60 wt% of the pre-roller blend to provide sufficient binding sites without producing oversized dense flakes that require secondary milling. Process controls are aligned to USP <1062> for compaction characterization, USP <1174> for powder flow, Ph.Eur. 2.9.34 for bulk density, and ICH Q3D. The downstream sequence uses a roller compactor with roll speed 5–15 rpm, gap 1.5–3.0 mm, and hydraulic pressure 4–8 MPa; the ribbons are milled through a 0.8–1.5 mm screen to produce granules with fines fraction below 30%. The terminal product is a dry-granulated tablet or capsule fill for moisture-sensitive or high-dose actives where wet granulation is incompatible. At pressures above 8 MPa, the saccharide undergoes work hardening and the resulting granules exhibit a measurable loss in tableting compressibility, requiring a rebound in main compression force of 10–20% to maintain hardness; therefore the pressure ceiling is fixed at 8 MPa for standard formulations.

In orally disintegrating tablet manufacture, Compressol™ ProTab serves as the principal matrix former at 60–85 wt%, combined with a superdisintegrant at 3–8 wt% and a polyol such as mannitol at 10–20 wt%. The finished tablet is tested to USP <701> disintegration, Ph.Eur. 2.9.1, USP <905>, and USP <1216> friability, with target disintegration time below 30 s and friability below 1.0%. The downstream process uses low-compression-force rotary press settings of 8–15 kN with B-tooling to produce tablets of 50–200 mg and hardness 20–40 N; blending is performed at 15 rpm for 10 min to avoid overmixing the friable matrix. The terminal product is an orally disintegrating tablet for patients with dysphagia or for pediatric use. The operational boundary is the hardness–friability trade-off: exceeding 15 kN increases disintegration time above 30 s, while reducing compression force below 8 kN raises edge chipping during de-dusting and packaging. Published data for the specific combination of Compressol™ ProTab with all available superdisintegrant grades is limited, so formulation trials should confirm disintegrant compatibility under 40°C/75% RH accelerated storage.

Effervescent Granule Stability Under Low-RH Processing

Effervescent granule stability under low-RH processing requires Compressol™ ProTab to be incorporated at 10–35 wt% of the acid-carbonate reaction mass as a sweetening and bodying agent. The compliance package includes USP <731> loss on drying, Ph.Eur. 2.2.32 residual moisture determination, USP <1151> pharmaceutical dosage forms, and ICH Q3D. The downstream process separates citric acid and sodium bicarbonate granulation into two stages; Compressol™ ProTab is pre-dried to moisture <0.3%, blended with each component at 15 rpm for 8–12 min, and granulated with ethanol or isopropanol at 3–5% w/w in a fluid-bed unit with inlet air temperature 35–50°C. Final granules are dried to residual moisture <0.2%, lubricated with 0.5% w/w sodium benzoate, and compressed at 20–40 kN or filled into moisture-barrier sachets. The terminal product is an effervescent tablet or granule sachet for oral solution. The critical processing limit is humidity: at ambient relative humidity above 20% RH, the saccharide surface accelerates localized acid-carbonate reaction, causing pre-effervescence and granule collapse; all transfer and compression stages must therefore be maintained under dehumidified air at 15–20% RH.

In lyophilized injectable formulation, the pharma-grade Compressol™ ProTab is used as a bulking and lyoprotective saccharide at 2–10% w/v in the pre-lyophilization solution, depending on target cake structure and osmotic contribution. The quality requirements are governed by USP <1> Injections and Implanted Drug Products, USP <785> osmolality, USP <85> bacterial endotoxins test, Ph.Eur. 2.2.35 osmolality, and ICH Q3D. The downstream process dissolves the saccharide in Water for Injection at 20–25°C, followed by filtration through a 0.22 μm sterilizing membrane, filling into depyrogenated glass vials, and loading into a freeze dryer. A typical cycle includes shelf cooling to -40°C for 2 h, primary drying at -20°C and 0.2 mbar for 24 h, and secondary drying at 30°C for 4–8 h to residual moisture below 1.0%. The terminal product is a sterile lyophilized powder or cake for reconstitution by intravenous or intramuscular injection. The operational boundary is the tonicity window: above 10% w/v, the solution becomes hypertonic and may require adjustment with a non-saccharide tonicity agent; below 2% w/v, cake collapse may occur if the active concentration is low and annealing is omitted.